Interferon-β1b for the treatment of multiple sclerosis

Expert Opinion on Drug Metabolism and Toxicology

Volumn 4, Issue 8, 2008, Pages 1111-1117

  Lam, Sum ^a,b   Wang, Shan ^b   Gottesman, Malcolm ^b,c  

^a ST JOHN'S UNIVERSITY   (United States)

^b WINTHROP UNIVERSITY HOSPITAL   (United States)

^c STONY BROOK UNIVERSITY   (United States)

Author keywords

Disease modifying therapy; IFN ; Immune modulators; Multiple sclerosis

Indexed keywords

ALEMTUZUMAB; BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; MITOXANTRONE; NATALIZUMAB; PLACEBO; RITUXIMAB; BETA INTERFERON; IMMUNOLOGICAL ADJUVANT; INTERFERON BETA-1B; PEPTIDE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANTIVIRAL ACTIVITY; ASTHENIA; AUTOIMMUNE DISEASE; CARDIOTOXICITY; CHILL; CLINICAL FEATURE; CLINICAL ISOLATED SYNDROME; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DEMYELINATING DISEASE; DEPRESSION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FLU LIKE SYNDROME; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; IMMUNOREGULATION; INJECTION SITE INFLAMMATION; INJECTION SITE NECROSIS; INJECTION SITE REACTION; LEUKOPENIA; LIPODYSTROPHY; LOW DRUG DOSE; LYMPHADENOPATHY; LYMPHOCYTOPENIA; MENSTRUATION DISORDER; MULTIPLE SCLEROSIS; MUSCLE HYPERTONIA; MUSCLE STIFFNESS; MYALGIA; MYASTHENIA; PARESTHESIA; PATHOPHYSIOLOGY; PREVALENCE; RECURRENCE RISK; REVIEW; SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS; SEX DIFFERENCE; SIDE EFFECT; SPASTICITY; SUICIDAL IDEATION; SYSTEMIC DISEASE; UPPER RESPIRATORY TRACT INFECTION;

ADJUVANTS, IMMUNOLOGIC; CLINICAL TRIALS AS TOPIC; HUMANS; INTERFERON-BETA; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PEPTIDES;

EID: 51049109380     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.4.8.1111     Document Type: Review

References (26)

1. National Multiple Sclerosis Society. Available from: www.nationalmssociety.org [Last accessed on December 29; 2007]
2. Mayo Foundation for Medical Education and Research. Available from: http://mayoresearch.mayo.edu. [Last accessed on December 29; 2007]
3. Lacy, Armstrong, Goldman, Lance. Drug information handbook, lexi-comp's drug reference handbook. 15th edition, 2007-2008
4. Micromedex Thomson Healthcare Series. Available from: www.micromedex.com [accessed on 29 December 2007]
5. Betaseron® Prescribing Information. Bayer HealthCare Pharmaceuticals Inc. Montville, New Jersey, USA; 2007
6. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-61
7. Paty DW, Li DK. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 1993;43:662-7
8. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 1995;45:1277-85
9. Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002;359:1453-60
10. Barbero P, Bergui M, Versino E, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: analysis of MRI responses to treatment and correlation with Nab. Mult Scler 2006;12:72-6
11. Koch-Henriksen N, Sørensen PS, Christensen T, et al. A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. Neurology 2006;66:1056-60
12. Etemadifer M, Janghorbani M, Shaygannejad V. Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis. Acta Neurol Scand 2006;113:283-7
13. Flechter S, Vardi J, Pollak L, Rabey JM. Comparison of glatiramer acetate (Copaxone) and interferon beta-1b (Betaferon) in multiple sclerosis patients: an open-label 2-year follow-up. J Neurol Sci 2002;197:51-5
14. Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006;67:1242-9
15. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS. Lancet 1998;352:1491-7
16. Panitch H, Miller A, Paty D, Weinshenker B. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 2004;63:1788-95
17. Coyle PK. Evidence-based medicine and clinical trials. Neurology 2007;68:S3-7
18. Kappos L, Weinshenker B, Pozzilli C, et al. Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials. Neurology 2004;63:1779-87
19. BEYOND study press release. Available from: http://www.betaseron.com/pdf/ BeyondStudy102907.pdf. Accessed March 27, 2008.
20. Wolansky LJ, Haghighi MH, Sevdalis E, et al. Safety of serial monthly administration of triple-dose gadopentetate dimeglumine in multiple sclerosis patients: preliminary results of the BECOME trial. J Neuroimaging 2005;15(3):289-90
21. CMSC MS research update: a webcast for healthcare professionals - the BECOME study. Available from: http://www.mscare.org/cmsc/ Webcast-Become-Study.html [Last accessed March 27; 2008]
22. Goodin DS, Frohman EM, Hurwitz B, et al. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2007;68(13):977-84
23. Study suggests Copaxone® treatment reduces risk of developing MS. Available from: http://www.nationalmssociety.org/news/news-detail/ index.aspx?nid=69 [Last accessed 31 March 2008]
24. Hauser S, Waubant E, Arnold D, et al. A phase II randomized, placebo-controlled, multicenter trial of rituximab in adults with relapsing remitting multiple sclerosis (RRMS) [abstract]. Neurology 2007;68(Suppl 1):A99
25. Coles AJ; the CAMMS223 Study Group. Efficacy of alemtuzumab in treatment-naïve relapsing-remitting multiple sclerosis: analysis after two years of study CAMMS223 [abstract]. Neurology 2007;68(Suppl 1):A100
26. Coles AJ, Cox A, Le Page E, et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 2006;253:98-108